20:39 , Feb 17, 2017 |  BioCentury  |  Finance

NexImmune’s next act

Management’s and investors’ different views about what product to develop first was the catalyst for the sale of immuno-oncology play NexImmune Inc. to a new syndicate led by Sol Barer, chairman of Teva Pharmaceutical Industries...